Kiniksa Pharmaceuticals International, plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KNSA | KY4.F | BCRX | KILITCH.NS | KRK.WA | MRK.F | |
|---|---|---|---|---|---|---|
| Market cap | 7.55B | 7.59B | 2.11B | 7.29B | 33.00B | 65.87B |
| P/E (TTM) | 72.8 | 16.9 | — | 23.7 | 18.6 | 27.8 |
| Forward P/E | 44.0 | 17.7 | 10.0 | 13.6 | — | 16.7 |
| Price/book | 10.6 | 1.5 | -14.7 | 2.6 | 12.6 | 2.2 |
| Dividend yield | — | 2.89% | — | — | 3.61% | 1.49% |
| 1-year change | +148.82% | +1.49% | +17.21% | +3.92% | +22.70% | +37.23% |
| Today | +3.03% | +6.62% | −3.85% | −0.21% | −0.18% | +0.50% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All KNSA news ›Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells $3,424,031.80 in Stock
Check Out Our Latest Report on Kiniksa Pharmaceuticals International Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of…
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
On its third quarter of 2026 earnings call, held on Oct. 27, 2026, Kiniksa Pharmaceuticals (KNSA +20.98%) announced that it raised its full-year 2026 revenue guidance to between $1.045 billion and $1.050 billion. Generating profitable…
Kiniksa targets $1.045B-$1.050B 2026 revenue as KPL-387 data expected in H2 2027
Kiniksa Q3 2026 earnings: raised revenue guidance, strong ARCALYST growth, and KPL-387 timeline updates. Earnings Call Insights: Kiniksa Pharmaceuticals (KNSA) Q3 2026 - “This morning, we announced via a press release that we’ve raised our…
Citi Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)
Citi analyst Geoff Meacham maintained a Buy rating on Kiniksa Pharmaceuticals today and set a price target of $100.00. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Bristol-Myers Squibb, and Regeneron. According…
Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
Kiniksa Pharmaceuticals (KNSA) stock jumps as the company's Q3 results beat expecations thanks to Regeneron (REGN)-partnered Arcalyst. Read more here. Kiniksa Pharmaceuticals (KNSA) climbed nearly 20% to hit a new 52-week high on Tuesday…
Kiniksa Pharmaceuticals International, plc 2026 Q3 - Results - Earnings Call Presentation
2026-10-27. The following slide deck was published by Kiniksa Pharmaceuticals International, plc in conjunction with their 2026 Q3 earnings call. The following slide deck was published by Kiniksa Pharmaceuticals International, plc in…
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS
Posted by Danessa Lincoln on Oct 27th, 2026 KNSA opened at $72.98 on Tuesday. The business has a 50-day moving average of $78.03 and a 200-day moving average of $59.00. Kiniksa Pharmaceuticals International has a fifty-two week low of…
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Review
Posted by Defense World Staff on Oct 25th, 2026 Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both mid-cap healthcare companies, but which is the superior…
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High - Still a Buy?
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded at $83.17, with a volume of 1,235,582…
Kiniksa Pharmaceuticals International (KNSA) Expected to Post Quarterly Earnings on Tuesday
Shares of KNSA stock opened at $79.48 on Tuesday. The stock has a market cap of $6.20 billion, a P/E ratio of 81.94 and a beta of 0.04. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $82.98. The…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketbeat.com4
- themarketsdaily.com4
- seekingalpha.com3
- defenseworld.net2
- fool.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.